optimization of standard aml treatment: apl advances, adverse cytogenetics & post-remission therapy
Published 6 years ago • 328 plays • Length 11:35Download video MP4
Download video MP3
Similar videos
-
7:52
advances in aml understanding: apl therapy, immunotherapy and maintenance therapy
-
2:34
the evolution of the aml treatment paradigm
-
1:41
the importance of integrating genomic and cytogenetic data in treatment decisions for aml
-
2:09
advances in the management of fit adults with aml
-
3:47
the impact of cytogenetic-risk stratification on aml outcomes
-
2:58
evolution of the aml treatment paradigm
-
3:14
determining the optimal frontline treatment of aml
-
7:46
updates in aml treatment and research from asco 2023
-
11:06
how could new treatment options improve outcomes in flt3-mutated aml?
-
28:19
diagnosis: morphology, flow cytometry, cytogenetics, molecular testing, and risk-stratification
-
1:28
the role of allogeneic transplantation in patients with aml in the frontline setting
-
1:39
optimizing chemotherapy in aml
-
1:33
sorafenib as maintenance therapy for patients with transplant-ineligible or post-allosct aml
-
1:59
optimizing the use of flt3 inhibitors in aml: sequencing, post-transplant maintenance & more
-
8:21
quazar aml-001: a new standard for aml maintenance therapy
-
0:53
an overview of optimal sequencing therapy in aml
-
0:52
a real-world study of the optimal duration of cpx-351 treatment in patients with aml
-
1:52
aml: the cytogenetic risk score
-
1:09
menin inhibitors for the treatment of aml: insights into the covalent-101 trial
-
1:46
optimizing conditioning regimens in patients with aml undergoing allosct
-
1:21
trends in allosct for good-risk aml: a longitudinal study
-
4:16
updates from amg 330 in aml